Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer : Safety lead‐in results from the QUATTRO-II study

• Material Type: 博士論文
• Title: Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer : Safety lead‐in results from the QUATTRO-II study
• Author/Editor: 小谷, 大輔
• Author Heading: 小谷, 大輔
• Publication Date: 2022-03-24
• Publication Date (W3CDTF): 2022-03-24
• Alternative Title: 切除不能進行・再発大腸癌に対する一次治療としてのカペシタビン、イリノテカン、オキサリプラチン、ベバシズマブ併用療法 : QUATTRO-II試験の安全性導入パート結果
• Degree Grantor: 香川大学; Kagawa University
• Date Granted: 2022-03-24
• Date Granted (W3CDTF): 2022-03-24
• Dissertation Number: 甲第797号
• Degree Type: 博士（医学）
• Conferring No. (Dissertation): 甲第797号
• Text Language Code: eng
• Subject Heading: Metastatic colorectal cancer; CAPOXIRI; Triplet; Bevacizumab; FOLFOXIRI
• Target Audience: 一般
• Note (General): 出版タイプ： P; 機関リポジトリ記載の権利情報: Copyright © 2021, The Author(s).; 機関リポジトリ記載の権利情報: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.; 機関リポジトリ記載の権利情報: http://creativecommons.org/licenses/by/4.0/
• Persistent ID (NDL): info:ndljp/pid/12263393; https://dl.ndl.go.jp/pid/12263393
• Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• Acquisition Basis: 博士論文（自動収集）
• Date Accepted (W3CDTF): 2022-05-09T11:57:37+09:00
• Format (IMT): PDF
• Access Restrictions: 国立国会図書館内限定公開
• Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
• Availability of remote photoduplication service: 可
• Periodical Title (URI): https://kagawa-u.repo.nii.ac.jp/records/9548
• Is Version Of (URI): https://doi.org/10.1007/s10637-021-01125-2
• Has Version (URI): http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8541955/
• Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

• Summary, etc.: Background: FOLFOXIRI plus bevacizumab is the first-line treatment for metastatic colorectal cancer (mCRC) but demonstrates high neutropenia incidence...